13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001842545
Total reported value
$603.3M
$603.3M
26 檔
38.8%
As reported in its official Q2 2024 Form 13F filing, Eagle Health Investments LP's tracked investment portfolio stood at $603.3M with 26 total positions.
During Q2 2024, Eagle Health Investments LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | UTHR | United Therapeutics CORP | Stock-Healthcare | 9.36% | — | -6.69% | |
| 2 | NTRA | Natera Inc | Stock-Healthcare | 9.00% | -3.55% | -25.07% | |
| 3 | ICLR | ICON Public Limited Company | Stock-Healthcare | 8.22% | +1.93% | — | |
| 4 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 7.76% | — | — | |
| 5 | ARGX | Argenx Se - Adr | Stock-Healthcare | 6.70% | +2.00% | +5.08% | |
| 6 | INSM | Insmed Inc | Stock-Healthcare | 6.04% | +0.38% | — | |
| 7 | ILMN | Illumina Inc | Stock-Healthcare | 5.83% | +1.42% | — | |
| 8 | DXCM | Dexcom Inc | Stock-Healthcare | 5.48% | — | -3.23% | |
| 9 | IQV | Iqvia Holdings Inc | Stock-Healthcare | 4.52% | — | — | |
| 10 | EXK | Exact Sciences CORP | Stock-Materials | 4.03% | — | +349.75% | |
| 11 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 3.78% | +1.65% | +75.01% | |
| 12 | TMDX | Transmedics Group Inc | Stock-Healthcare | 3.51% | — | -52.32% | |
| 13 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 3.35% | +0.92% | — | |
| 14 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 3.25% | — | +57.70% | |
| 15 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 3.21% | — | +11.78% | |
| 16 | GH | Guardant Health Inc | Stock-Healthcare | 3.18% | +2.47% | -14.15% | |
| 17 | PRCT | Procept Biorobotics CORP | Stock-Other | 2.75% | -2.51% | EXIT | |
| 18 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 2.50% | — | — | |
| 19 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 2.21% | -0.06% | -20.51% | |
| 20 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 1.87% | — | — | |
| 21 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 1.70% | — | — | |
| 22 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 0.61% | — | — | |
| 23 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.42% | — | — | |
| 24 | HOWL | Werewolf Therapeutics Inc | Stock-Other | 0.30% | — | — | |
| 25 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.28% | — | — | |
| 26 | GRAL | Grail Inc | Stock-Healthcare | 0.14% | — | — |
According to official SEC Form 13F filings, Eagle Health Investments LP reported a total U.S. public equity portfolio value of $603.3M across 26 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including UTHR, NTRA, ICLR) accounted for 38.8% of total reported equity market value during Q2 2024.
During Q2 2024, Eagle Health Investments LP's top holdings by market value included UTHR (9.4%)、NTRA (9.0%)、ICLR (8.2%). The largest single position, UTHR, represented 9.4% of total portfolio value.
In Q2 2024, Eagle Health Investments LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.